1. Home
  2. ZURA vs LOCO Comparison

ZURA vs LOCO Comparison

Compare ZURA & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$5.23

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$15.93

Market Cap

411.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
LOCO
Founded
2022
1980
Country
United States
United States
Employees
40
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
411.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ZURA
LOCO
Price
$5.23
$15.93
Analyst Decision
Buy
Buy
Analyst Count
6
4
Target Price
$13.00
$14.17
AVG Volume (30 Days)
1.5M
251.9K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
4.65
EPS
N/A
0.27
Revenue
N/A
$401,701,000.00
Revenue This Year
N/A
$3.60
Revenue Next Year
N/A
$3.98
P/E Ratio
N/A
$57.19
Revenue Growth
N/A
5.68
52 Week Low
$1.35
$8.99
52 Week High
$7.25
$17.40

Technical Indicators

Market Signals
Indicator
ZURA
LOCO
Relative Strength Index (RSI) 52.35 47.85
Support Level $5.17 $15.84
Resistance Level $5.88 $17.21
Average True Range (ATR) 0.40 0.41
MACD -0.03 -0.18
Stochastic Oscillator 40.12 30.36

Price Performance

Historical Comparison
ZURA
LOCO

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.

Share on Social Networks: